Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Prednisone 102enzalutamide 74Docetaxel 72Abiraterone Acetate 67Leuprolide 47acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45abiraterone 37apalutamide 28Prednisolone 27bicalutamide 26Zoledronic Acid 24pembrolizumab 22Goserelin 22radium Ra 223 dichloride 21darolutamide 21Triptorelin Pamoate 17cabazitaxel 15Androgen Antagonists 15sipuleucel-T 13luprolide acetate gel depot 12Injections 12Dexamethasone 12olaparib 11gallium 68 PSMA-11 10Mitoxantrone 10Pluvicto 9Ipilimumab 9Dutasteride 9Cyclophosphamide 9relugolix 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms × Registries × Clear all
NCT02454595 2017-09-05

Registry to Measure the Impact of Adding Genomic Testing

Myriad Genetic Laboratories, Inc.

Terminated
116 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡